Progyny, Inc. (PGNY) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US74340E1038

Price
28.13 USD
Market cap
2.16 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Progyny, Inc. financials

Fiscal year2025
Revenue1.29 bn USD
Gross profit304.48 m USD
Operating income85.28 m USD
EBIT95.43 m USD
Net income58.52 m USD
Diluted EPS – continuing operations0.65 USD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Progyny, Inc.

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 26.10.2026. Details in the risk notice.